Top Buy
| Security | Buy | Sell | Buy (1M) | Sell (1M) | Price | Target price | Potential |
|---|---|---|---|---|---|---|---|
| Alnylam Pharmace. | 36 | 0 | 3 | 0 | €140.00 | €228.30 | 63.071% |
| Neurocrine Bioscience | 27 | 0 | 7 | 0 | €130.30 | €140.34 | 7.705% |
| United Therapeutics | 18 | 0 | 3 | 0 | €240.90 | €288.66 | 19.826% |
| Exelixis Inc. | 17 | 0 | 2 | 0 | €20.62 | €25.64 | 24.322% |
| Merit Medical Systems | 16 | 0 | 5 | 0 | €69.50 | €86.90 | 25.032% |
| Ultragenyx Pharmaceutical Inc. | 16 | 1 | 3 | 0 | €40.40 | €82.93 | 105.275% |
| Insulet Corp. | 14 | 0 | 1 | 0 | €161.70 | €215.54 | 33.295% |
| Halozyme Therapeutics Inc. | 13 | 0 | 2 | 0 | €37.15 | €53.50 | 43.998% |
| Repligen Corp. | 13 | 0 | 1 | 0 | €155.15 | €184.76 | 19.085% |
| Amedisys Inc. | 13 | 0 | 0 | 0 | €84.50 | €92.26 | 9.183% |
| Bio-Techne Corp. | 10 | 0 | 2 | 0 | €70.50 | €75.80 | 7.522% |
| CONMED Corp. | 11 | 1 | 3 | 0 | €62.50 | €109.59 | 75.336% |
| Medpace Holdings Inc | 9 | 0 | 3 | 0 | €364.50 | €421.61 | 15.667% |
| PTC Therapeutics Inc. | 14 | 5 | 3 | 0 | €29.80 | €41.51 | 39.304% |
| Ensign Group Inc. | 8 | 0 | 1 | 0 | €110.00 | €116.50 | 5.906% |
| Xencor Inc. | 9 | 1 | 1 | 0 | €18.70 | €31.74 | 69.727% |
| Bruker Corp. | 7 | 1 | 0 | 1 | €65.32 | €85.68 | 31.176% |
| Masimo Corp. | 7 | 1 | 2 | 0 | €127.05 | €147.62 | 16.187% |
| Agios Pharmaceuticals Inc. | 5 | 0 | 2 | 0 | €30.60 | €38.99 | 27.414% |
| Myriad Genetics | 5 | 2 | 0 | 0 | €18.30 | €23.22 | 26.872% |
| Icu Medical Inc. | 3 | 0 | 0 | 0 | €91.00 | €124.85 | 37.195% |
| Nektar Therapeutics | 3 | 1 | 1 | 0 | €1.55 | €3.70 | 138.402% |
| Davita Inc. | 2 | 0 | 0 | 0 | €132.60 | €124.89 | -5.816% |
| Healthequity Inc. | 1 | 0 | 0 | 0 | €73.50 | €79.00 | 7.483% |
| Blueprint Medicines Corp | 1 | 0 | 1 | 0 | €99.70 | - | - |